Study on Amivantamab with Lazertinib or Chemotherapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Inclusion Criteria

• Have advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be treated with surgery aimed at curing the disease.
• Have a specific type of EGFR mutation, either Ex19del or Ex21 L858R, confirmed by an approved test in a certified laboratory.
• Have at least one tumor that can be measured and has not been treated with radiation.
• Any side effects from previous cancer treatments must have improved to a mild level or returned to normal, except for hair loss, mild nerve damage, or mild thyroid issues that are stable with medication.
• Be in good overall health, with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.

Exclusion Criteria

• Have a history of active lung diseases like interstitial lung disease or radiation-induced lung inflammation.
• Have had major surgery or a significant injury within four weeks before starting the study treatment, or not fully recovered from surgery, or have surgery planned during the study.
• Have uncontrolled pain from the cancer that has not been treated with radiation.
• Have received an experimental treatment that has not been cleared or within 12 months before starting the study treatment, or are currently in another experimental study.
• Have another type of cancer that could interfere with the study's safety or effectiveness results.